SecukinumabQualityChecker

Secukinumab

antivirals API biologics endotoxins essential medicines global market impurities injectables
Open selection

Secukinumab Quality Checker — Biologic Drug (Anti-IL-17A mAb) (Ph. Eur., USP)

ℹ️ The utility checks aggregates, potency, glycosylation, HCP, sterility, endotoxins, particles.
ℹ️ Does not use machine learning — rule-based logic only.
⚠️ CRITICAL! Aggregates ≤1.0%. Sterility mandatory. Endotoxins ≤1.0 EU/mg!

Usage:
SecukinumabQualityChecker.exe → demo mode
SecukinumabQualityChecker.exe input.csv output.json → evaluate data

Input format:
BatchNumber,Protein_Concentration_mgPerMl,Potency_Percent,pH_Value,Osmolality_mOsm_kg,Aggregate_Percent_SEC,Fragment_Percent_SEC,Acidic_Variants_Percent_IEC,Basic_Variants_Percent_IEC,Glycosylation_G0F_Percent,Host_Cell_Protein_ppm,Residual_DNA_ngPerMl,Protein_A_Leaching_ngPerMl,SterilityTest,Endotoxin_EU_per_mg,Subvisible_Particles_2_10_um,Subvisible_Particles_10_25_um,Subvisible_Particles_gt_25_um,Appearance_Score

Example:
SEC-BIO-2026-001,150.2,98.0,6.0,290,0.35,0.25,18.0,6.5,26.0,15,1.5,2.8,0,0.09,1100,110,7,0

— WHY IS THIS NEEDED?
Secukinumab — fully human IgG1κ monoclonal antibody against IL-17A for psoriasis, psoriatic arthritis, and ankylosing spondylitis treatment:
• Administered subcutaneously, so sterility and endotoxin requirements are maximum. Risk of severe skin reactions and immunogenicity is high.
• Aggregates (HMW): Critical parameter. Aggregates can cause severe immune responses and accelerated clearance. Limit is strict (≤1.0%).
• Potency: Measured by ability to neutralize IL-17A. Deviation leads to treatment inefficacy.
• Glycosylation: Sugar profile is critical for IgG1 stability and pharmacokinetics.
• Process Impurities: HCP (CHO cell proteins), DNA, and Protein A must be removed to trace levels.
• Particles: Subvisible particles are dangerous for injection, so control is strict.
⚠️ CRITICAL:
• Protein Concentration: 145.0–155.0 mg/mL (for 150 mg/mL form)
• Potency: 80–120% of standard
• Aggregates: ≤ 1.0%
• Glycosylation (G0F etc.): Within specified range (e.g., 10-40%)
• HCP: ≤ 50 ppm
• DNA: ≤ 10 ng/mL
• Sterility: No growth
• Endotoxins: ≤ 1.0 EU/mg
• Particles >25 µm: ≤ 60 counts/mL
• Appearance: Clear, colorless
⚠️ Note: Utility accounts for therapeutic antibody specifics (IgG1 subclass). Aggregate and glycosylation control is more important than for many other drugs as they directly impact safety (immunogenicity) and efficacy (IL-17A blockade). Sterility is absolute requirement. Deamidation (acidic peaks) controlled as stability marker during storage.

input.csv

BatchNumber,Protein_Concentration_mgPerMl,Potency_Percent,pH_Value,Osmolality_mOsm_kg,Aggregate_Percent_SEC,Fragment_Percent_SEC,Acidic_Variants_Percent_IEC,Basic_Variants_Percent_IEC,Glycosylation_G0F_Percent,Host_Cell_Protein_ppm,Residual_DNA_ngPerMl,Protein_A_Leaching_ngPerMl,SterilityTest,Endotoxin_EU_per_mg,Subvisible_Particles_2_10_um,Subvisible_Particles_10_25_um,Subvisible_Particles_gt_25_um,Appearance_Score
SEC-BIO-2026-001,150.2,98.0,6.0,290,0.35,0.25,18.0,6.5,26.0,15,1.5,2.8,0,0.09,1100,110,7,0

URS & FS — user requirements and functional specification

This document defines user requirements and functional specification for the quality-control utility. It supports deployment discussion, IQ/OQ preparation and QC workflow integration.

Utility: SecukinumabQualityCheckerAPI / object: SecukinumabCategory: Global API expansion

1. Scope

The Secukinumab Quality Checker utility is used for Secukinumab. The actual input.csv is the source of truth for the input structure; control criteria are defined by the executable and the domain description.

The utility does not use machine learning; decisions are produced by deterministic rules.

Categories: Global API expansion

Tags: antivirals, API, biologics, endotoxins, essential medicines, global market, impurities, injectables, oncology, sterility

2. Execution modes

SecukinumabQualityChecker.exe                            → demo mode
SecukinumabQualityChecker.exe input.csv output.json      → evaluate data

3. Key controlled areas

  • assay / content
  • microbiology and pathogens
  • pH and physicochemical parameters

4. Domain limits and critical parameters

  • ⚠️ CRITICAL! Aggregates ≤1.0%. Sterility mandatory. Endotoxins ≤1.0 EU/mg!
  • Aggregates (HMW): Critical parameter. Aggregates can cause severe immune responses and accelerated clearance. Limit is strict (≤1.0%).
  • ⚠️ CRITICAL:
  • Protein Concentration: 145.0–155.0 mg/mL (for 150 mg/mL form)
  • Potency: 80–120% of standard
  • Aggregates: ≤ 1.0%
  • Glycosylation (G0F etc.): Within specified range (e.g., 10-40%)
  • HCP: ≤ 50 ppm
  • DNA: ≤ 10 ng/mL
  • Sterility: No growth
  • Endotoxins: ≤ 1.0 EU/mg
  • Particles >25 µm: ≤ 60 counts/mL
  • Appearance: Clear, colorless
  • ⚠️ Note: Utility accounts for therapeutic antibody specifics (IgG1 subclass). Aggregate and glycosylation control is more important than for many other drugs as they directly impact safety (immunogenicity) and efficacy (IL-17A blockade). Sterility is absolute requirement. Deamidation (acidic peaks) controlled as stability marker during storage.
Limits stated in the description must be verified against the current approved specification, pharmacopoeial monograph and registration dossier before production use.

5. URS — user requirements

IDRequirementCriticalityAcceptance criterion
URS-001The system shall accept an input.csv file for Secukinumab with the exact columns listed in the “Input data contract” section.HighA file with the correct header is processed without manual editing; missing mandatory columns produce FAIL/import error.
URS-002The system shall support execution without arguments in demo mode and execution with input.csv output.json for user data.MediumBoth execution scenarios produce a predictable result or clear diagnostic error.
URS-003The system shall perform rule-based controls for: assay / content, microbiology and pathogens, pH and physicochemical parameters.HighEach controlled parameter receives a status and message; the result does not depend on hidden Excel formulas or ML.
URS-004The system shall preserve traceability between batch/lot, source values, applied rules and final verdict.HighOutput includes batch identifier, source values, parameter statuses and critical findings.
URS-005The system shall generate machine-readable output.json for LIMS/ELN/MES, batch record and QA/QC review.HighJSON contains overall status, check array, warnings, failures and source-file reference.
URS-006The system shall support use in the client validation package: URS/FS, IQ/OQ preparation, installation and operational scenario checks.HighThe document, test scenarios and reproducible CSV/JSON flow are suitable for audit and internal approval.
URS-007The system shall clearly separate technical data errors from specification nonconformities.MediumSchema/type errors are not mixed with pharmacopoeial deviations and are reported separately.

6. input.csv data contract

The source of truth for the input schema is the actual input.csv header. Column names are technical identifiers and are not translated.

#ColumnTypeUnitDescriptionSampleControl rule
1BatchNumberidentifieras specifiedBatch NumberSEC-BIO-2026-001mandatory field; used for batch/lot traceability
2Protein_Concentration_mgPerMldecimalmg/mlProtein Concentration mg per Ml150.2numeric value; compared with assay/purity limit from specification or method
3Potency_Percentdecimal%Potency %98.0mandatory numeric value; rule comparison is performed by the utility
4pH_ValuedecimalpHp H Value6.0mandatory numeric value; rule comparison is performed by the utility
5Osmolality_mOsm_kgdecimalmOsm/kgOsmolality m Osm kg290mandatory numeric value; rule comparison is performed by the utility
6Aggregate_Percent_SECdecimal%Aggregate % SEC0.35mandatory numeric value; rule comparison is performed by the utility
7Fragment_Percent_SECdecimal%Fragment % SEC0.25mandatory numeric value; rule comparison is performed by the utility
8Acidic_Variants_Percent_IECdecimal%Acidic Variants % IEC18.0mandatory numeric value; rule comparison is performed by the utility
9Basic_Variants_Percent_IECdecimal%Basic Variants % IEC6.5mandatory numeric value; rule comparison is performed by the utility
10Glycosylation_G0F_Percentdecimal%Glycosylation G0 F %26.0mandatory numeric value; rule comparison is performed by the utility
11Host_Cell_Protein_ppmdecimalppmHost Cell Protein ppm15mandatory numeric value; rule comparison is performed by the utility
12Residual_DNA_ngPerMldecimalas specifiedResidual DNA ng per Ml1.5mandatory numeric value; rule comparison is performed by the utility
13Protein_A_Leaching_ngPerMldecimalas specifiedProtein A Leaching ng per Ml2.8mandatory numeric value; rule comparison is performed by the utility
14SterilityTestboolean / flag0/1Sterility Test0valid flag required; prohibited organisms and growth are normally expected as 0 / absent
15Endotoxin_EU_per_mgdecimalEU/mlEndotoxin EU per mg0.09numeric value; critical safety attribute compared with endotoxin limit
16Subvisible_Particles_2_10_umdecimalµmSubvisible Particles 2 10 um1100mandatory numeric value; rule comparison is performed by the utility
17Subvisible_Particles_10_25_umdecimalµmSubvisible Particles 10 25 um110mandatory numeric value; rule comparison is performed by the utility
18Subvisible_Particles_gt_25_umdecimalµmSubvisible Particles gt 25 um7mandatory numeric value; rule comparison is performed by the utility
19Appearance_Scoredecimalas specifiedAppearance Score0mandatory numeric value; rule comparison is performed by the utility

CSV example

BatchNumber,Protein_Concentration_mgPerMl,Potency_Percent,pH_Value,Osmolality_mOsm_kg,Aggregate_Percent_SEC,Fragment_Percent_SEC,Acidic_Variants_Percent_IEC,Basic_Variants_Percent_IEC,Glycosylation_G0F_Percent,Host_Cell_Protein_ppm,Residual_DNA_ngPerMl,Protein_A_Leaching_ngPerMl,SterilityTest,Endotoxin_EU_per_mg,Subvisible_Particles_2_10_um,Subvisible_Particles_10_25_um,Subvisible_Particles_gt_25_um,Appearance_Score
SEC-BIO-2026-001,150.2,98.0,6.0,290,0.35,0.25,18.0,6.5,26.0,15,1.5,2.8,0,0.09,1100,110,7,0

7. FS — functional specification

IDFunctionImplementation description
FS-001CLI entry pointThe executable SecukinumabQualityChecker.exe supports demo mode and input.csv output.json processing mode.
FS-002CSV parserThe import module reads CSV, validates header, column presence/order, value count and encoding. Decimal values are expected with a dot separator.
FS-003Field conversionEach column is converted to the expected type: identifier, text, decimal number, date/time or boolean flag.
FS-004Domain rule engineFor Secukinumab, explicit rules are applied: range, minimum, maximum, absence of prohibited flag, data completeness or calculation-based check.
FS-005Criticality handlingCritical violations produce FAIL; non-critical deviations and incomplete data produce WARNING; full conformance produces PASS.
FS-006JSON writeroutput.json stores overall status, per-parameter results, source values, warnings, failures and diagnostic messages.
FS-007Integration contractThe CSV → JSON format is stable for invocation from LIMS/ELN/MES, scheduled task or wrapper service.
FS-008Error handlingSchema error, missing file, non-numeric value or JSON write failure returns diagnosable error without silent PASS.

8. output.json contract

The output file must be suitable for automated processing, audit review and correlation with the source input.csv row.

{
  "utility": "SecukinumabQualityChecker",
  "api": "Secukinumab",
  "batchNumber": "SEC-BIO-2026-001",
  "overallStatus": "PASS|WARNING|FAIL",
  "checkedAtUtc": "2026-05-18T00:00:00Z",
  "checks": [
    {
      "parameter": "BatchNumber",
      "value": "SEC-BIO-2026-001",
      "unit": "as specified",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "Protein_Concentration_mgPerMl",
      "value": "150.2",
      "unit": "mg/ml",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "Potency_Percent",
      "value": "98.0",
      "unit": "%",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "pH_Value",
      "value": "6.0",
      "unit": "pH",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "Osmolality_mOsm_kg",
      "value": "290",
      "unit": "mOsm/kg",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "Aggregate_Percent_SEC",
      "value": "0.35",
      "unit": "%",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "Fragment_Percent_SEC",
      "value": "0.25",
      "unit": "%",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "Acidic_Variants_Percent_IEC",
      "value": "18.0",
      "unit": "%",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    }
  ],
  "criticalFindings": [],
  "sourceFile": "input.csv"
}

9. OQ/PQ test scenarios

IDScenarioExpected result
TC-001Valid CSV with expected header and sample rowAll rows are processed; output contains PASS/WARNING/FAIL and parameter-level detail.
TC-002A mandatory input.csv column is missingImport is rejected or the row receives FAIL with schema reference.
TC-003A numeric field contains text or a blank valueType conversion error is recorded; the result is not hidden as PASS.
TC-004A parameter is outside specification or critical limitCritical parameters produce FAIL; non-critical deviations produce WARNING according to the rule.
TC-005Positive pathogen/microbiological flag or microbiological limit excursionCritical FAIL is produced with the offending parameter.

10. QA/QC, CSV and change control

  • Before production use, the client records executable version, checksum, specification/monograph version, test CSV, expected JSON and IQ/OQ results.
  • Column names must not be changed without updating the validator and test scenarios.
  • The source CSV, output.json and utility version should be stored together as an evidence package.
  • Any change in control rules must go through change control and repeated OQ scenario verification.

Included in packages

Australia: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

Biopharmaceuticals Core QC Suite

Focused QC utility package for biologic products: HCP, mAbs, biosimilars, proteins/peptides, sterility, endotoxins and key release checks.

Open

Biopharmaceuticals Extended QC Suite

Extended QC utility coverage for mAbs, biosimilars, proteins, insulins, vaccines, mRNA/LNP, HCP, sterile release, microbiology, water, cleanroom and stability workflows.

Open

Canada: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

France: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

Germany: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

Immunology QC Suite

QC utility package for immunology: monoclonal antibodies, biosimilars, immunomodulators, immunosuppressants, ELISA/SPR, HCP, protein characterization, sterility and pyrogen/release checks.

Open

Italy: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

Japan: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

Rheumatology QC Suite

QC package for rheumatology: NSAIDs, glucocorticoids, methotrexate, biologics and supporting impurity/potency checks.

Open

Russia: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

Saudi Arabia: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

South Korea: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

United Kingdom: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

United States: national essential medicines QC package

QC utility package aligned with the country essential/reimbursed medicines list analogue and cross-checked against WHO EML. Only utilities already present in the portal are included; the package is a validation/discussion starting map, not an official registry copy.

Open

World API Extension QC Suite

Extended package for 130 additional high-demand APIs and biological products prepared as a market-coverage backlog.

Open